M Bloch1,2, M John2,3,4, D Smith5,6, T A Rasmussen7,8, E Wright9,10,11. 1. Holdsworth House Medical Practice, Sydney, NSW, Australia. 2. Kirby Institute, University of New South Wales, Sydney, NSW, Australia. 3. Royal Perth Hospital, Perth, WA, Australia. 4. Institute of Immunology and Infectious Disease, Perth, WA, Australia. 5. School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW, Australia. 6. The Albion Centre, Sydney, NSW, Australia. 7. Doherty Institute for Infection and Immunity, Melbourne, Vic., Australia. 8. University of Melbourne, Melbourne, Vic., Australia. 9. The Alfred Hospital, Melbourne, Vic., Australia. 10. Centre for Inflammatory Diseases, Monash University, Melbourne, Vic., Australia. 11. The Burnett Institute, Melbourne, Vic., Australia.
Abstract
OBJECTIVES: This paper aims to address the concerns around ongoing immune activation, inflammation, and resistance in those ageing with HIV that represent current challenges for clinicians. METHODS: Presentations at a symposium addressing issues of ageing with HIV infection were reviewed and synthesised. RESULTS: The changing natural history and demographics of human immunodeficiency virus (HIV)-infected individuals means new challenges in contemporary management. In the early years of the epidemic,management was focussed on acute, potentially life-threatening AIDS-related complications. From initial monotherapy with first-generation antiretroviral therapy (ART), the development of combination highly active ART (HAART) allowed HIV control but ART toxicities, treatment adherence and drug resistance emerged as major issues. Today, the availability of potent and tolerable ART has made viral suppression achievable in most people living with HIV (PLHIV), and clinicians are confronted with managing a chronic condition among an ageing population. The combination of diseases of ageing and the co-morbidities associated with HIV-infection, even when well controlled, results in a complex set of challenges for many older PLHIV. There is a growing appreciation that many non-AIDS-related co-morbidities are caused, at least in part, by persistent, low-grade immune activation, inflammation, and hypercoagulability, despite suppressive ART. CONCLUSIONS: In order to further improve HIV management, it is important to understand the enduring effects of chronically suppressed HIV infection, the potential contribution of these factors to the ageing process, the possibility of drug resistance, and the impact of different treatment strategies, including early ART initiation.
OBJECTIVES: This paper aims to address the concerns around ongoing immune activation, inflammation, and resistance in those ageing with HIV that represent current challenges for clinicians. METHODS: Presentations at a symposium addressing issues of ageing with HIV infection were reviewed and synthesised. RESULTS: The changing natural history and demographics of human immunodeficiency virus (HIV)-infected individuals means new challenges in contemporary management. In the early years of the epidemic,management was focussed on acute, potentially life-threatening AIDS-related complications. From initial monotherapy with first-generation antiretroviral therapy (ART), the development of combination highly active ART (HAART) allowed HIV control but ART toxicities, treatment adherence and drug resistance emerged as major issues. Today, the availability of potent and tolerable ART has made viral suppression achievable in most people living with HIV (PLHIV), and clinicians are confronted with managing a chronic condition among an ageing population. The combination of diseases of ageing and the co-morbidities associated with HIV-infection, even when well controlled, results in a complex set of challenges for many older PLHIV. There is a growing appreciation that many non-AIDS-related co-morbidities are caused, at least in part, by persistent, low-grade immune activation, inflammation, and hypercoagulability, despite suppressive ART. CONCLUSIONS: In order to further improve HIV management, it is important to understand the enduring effects of chronically suppressed HIV infection, the potential contribution of these factors to the ageing process, the possibility of drug resistance, and the impact of different treatment strategies, including early ART initiation.
Authors: Pariya L Fazeli; Amanda L Willig; Vitor Oliveira; Thomas W Buford; David E Vance; Greer Burkholder; Heidi M Crane; Christine Horvat Davey; Julia Fleming; Allison R Webel Journal: AIDS Behav Date: 2022-09-27
Authors: Janice J Endsley; Matthew B Huante; Kubra F Naqvi; Benjamin B Gelman; Mark A Endsley Journal: Retrovirology Date: 2021-06-16 Impact factor: 4.602